Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 1
2007 2
2008 3
2009 8
2010 13
2011 8
2012 13
2013 25
2014 20
2015 10
2016 18
2017 36
2018 28
2019 31
2020 48
2021 57
2022 53
2023 33
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Results by year

Filters applied: . Clear all
Page 1
Impact of severe acute kidney injury on short-term mortality in urosepsis.
Fujita N, Momota M, Soma O, Noro D, Mikami J, Miura Y, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C, Hatakeyama S. Fujita N, et al. Among authors: hatakeyama s. World J Urol. 2024 May 8;42(1):301. doi: 10.1007/s00345-024-05018-w. World J Urol. 2024. PMID: 38717511
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
Fujita N, Hatakeyama S, Tabata R, Okita K, Kido K, Hamano I, Tanaka T, Noro D, Tokui N, Suzuki Y, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Fujita N, et al. Among authors: hatakeyama s. Prostate Int. 2024 Mar;12(1):46-51. doi: 10.1016/j.prnil.2023.12.002. Epub 2023 Dec 19. Prostate Int. 2024. PMID: 38523900 Free PMC article.
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.
Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K, Yajima S, Yashiro M, Yokoi K, Cho H, Ehira T, Nakahara K, Yasuda H, Isobe K, Hayashida T, Hatakeyama S, Akakura K, Aoki D, Nomura H, Tada Y, Yoshimatsu Y, Miyachi H, Takebayashi C, Hanamura I, Takahashi H. Kikuchi Y, et al. Among authors: hatakeyama s. Int J Clin Oncol. 2024 May;29(5):512-534. doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17. Int J Clin Oncol. 2024. PMID: 38493447
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y; Japanese Urological Oncology Group. Matsuda A, et al. Among authors: hatakeyama s. BJU Int. 2024 Feb 12. doi: 10.1111/bju.16296. Online ahead of print. BJU Int. 2024. PMID: 38344879
Incidence of postoperative cytomegalovirus and BK-polyoma virus infections and graft loss in ABO-incompatible renal transplant recipients: a multicenter retrospective study.
Kodama H, Hatakeyama S, Matsuura T, Saito M, Nishida H, Hamaya T, Maita S, Murakami R, Tomita H, Saitoh H, Tsuchiya N, Habuchi T, Obara W, Ohyama C. Kodama H, et al. Among authors: hatakeyama s. Int Urol Nephrol. 2024 Feb 9. doi: 10.1007/s11255-023-03934-1. Online ahead of print. Int Urol Nephrol. 2024. PMID: 38332424
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group. Matsushita Y, et al. Among authors: hatakeyama s. Int J Urol. 2024 May;31(5):526-533. doi: 10.1111/iju.15396. Epub 2024 Jan 19. Int J Urol. 2024. PMID: 38240169
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
353 results